Catalog Advanced Search
Liver Transplantation and Surgery SIG & Surgery and Liver Transplantation Cmte: Combined Organ TransplantsContains 11 Component(s) Recorded On: 11/10/2018
AASLD's Liver Transplantation and Surgery SIG & Surgery and Liver Transplantation Cmte: Combined Organ Transplants presented at The Liver Meeting® 2018.
This program will review the current status of liver transplantation in the setting of combined organ transplants (i.e., liver/intestine/multi-visceral, liver/ kidney, liver/heart and liver/lung transplantation). Indications, pathophysiology, operative management, post-transplant care and outcomes will be discussed in the context of specific extra-hepatic organ dysfunction and combined organ transplantation. The session will also address the immunologic, ethical, financial and operational issues associated with multi-organ transplant as well as integration of these combined organ transplants in the overall liver allocation framework.
Richard Shane Mangus
Patrick S. Kamath
Josh Levitsky, MD, MS is currently a Professor of Medicine and Surgery in the Division of Gastroenterology & Hepatology at the Northwestern University Feinberg School of Medicine. Dr. Levitsky received his B.S. from the University of Michigan and M.D. from the Albert Einstein College of Medicine. He then completed an Internal Medicine residency and Gastroenterology fellowship at the University of Chicago Hospitals and a Transplant Hepatology fellowship at the University of Nebraska Medical Center, receiving an AASLD Fellowship Award. He is currently certified by the American Board of Internal Medicine in Gastroenterology and Transplant Hepatology. At Northwestern, he completed a Master of Science in Clinical Investigation, is the Director of Liver Research, and is the program director for both Gastroenterology and Transplant Hepatology Fellowships. He has been elected to the Northwestern Feinberg Academy of Medical Educators and has received several teaching awards.
Dr. Levitsky is an active member of several professional societies, including the American Society of Transplantation and International Liver Transplantation Society where he served on the executive boards, as well as the AASLD where he has served on several committees. He is a Deputy Editor for the American Journal of Transplantation and on the Editorial Board for HEPATOLOGY. Dr. Levitsky’s academic interests are clinical and translational in nature, with a focus on liver transplant immunosuppression, tolerance and biomarkers. He previously received an AASLD Career Development Award in Liver Transplantation and has published numerous peer-reviewed journal articles, abstracts, book chapters and reviews on topics relevant to liver disease and transplantation. He is the principal and co-investigator for a number of NIH, pharmaceutical and investigator-initiated trials. His goal is to advance clinical/translational research in immune-mediated liver diseases and liver transplantation, identifying biomarkers and novel strategies to optimize outcomes.
2018 Clinical Hepatology DebriefContains 2 Component(s) Recorded On: 11/13/2018
AASLD's Clinical Hepatology Debrief presented at The Liver Meeting® 2018.
This session provides a summary of the clinical highlights from The Liver Meeting®.
Jorge A. Bezerra (Moderator)
K. Rajender Reddy
2018 Hepatitis DebriefContains 2 Component(s) Recorded On: 11/13/2018
AASLD's Hepatitis Debrief presented at The Liver Meeting® 2018.
This session provides a synthesis of new data on the treatment of viral hepatitis presented at The Liver Meeting®.
Jorge A. Bezerra (Moderator)
Jordan J. Feld
Leon Schiff State-of-the-Art LectureContains 2 Component(s) Recorded On: 11/13/2018
AASLD's Leon Schiff State-of-the-Art Lecture presented at The Liver Meeting® 2018.
This lecture summarizes the current approach to understanding NASH pathogenesis, and how to translate recent advances into routine clinical care. Beginning with an overview of key pathogenic steps in development and progression of NASH, the program will also cover different therapeutic approaches for specific subsets of patients with NASH and related complications, and risk stratification of patients with respect to clinical outcomes.
Michael W. Fried (Moderator)
Arun J. Sanyal
2018 NAFLD DebriefContains 2 Component(s) Recorded On: 11/13/2018
AASLD's NAFLD Debrief presented at The Liver Meeting® 2018.
This session is designed to complement the highly-regarded, Hepatitis and Clinical Hepatology Debriefs, and will review key highlights from The Liver Meeting®.
Jorge A. Bezerra (Moderator)
Mary E. McCarthy Rinella
Hyman J. Zimmerman Hepatotoxicity State-of-the-Art LectureContains 2 Component(s) Recorded On: 11/12/2018
AASLD's Hyman J. Zimmerman Hepatotoxicity State-of-the-Art Lecture presented at The Liver Meeting® 2018.
Patients with underlying chronic liver disease (CLD) may develop drug-induced liver injury during clinical care or in clinical trials, and it is associated with poor outcomes. This lecture discusses medications and herbal agents that are commonly implicated in DILI, risk factors, strategies for monitoring patients in clinical trials, guidelines for adjudicating suspected DILI events and outcomes associated with DILI in CLD.
Raymond T. Chung (Moderator)
Naga P. Chalasani
2018 Advances for PractitionersContains 5 Component(s) Recorded On: 11/12/2018
AASLD's Advances for Practitioners presented at The Liver Meeting® 2018.
This program reviews the most recent advances in the clinical management of patients with cirrhosis. Topics of discussion include the use of beta blockers, anticoagulants and albumin for managing different complications of cirrhosis. Additionally, the most updated recommendations regarding screening issues for patients with cirrhosis will be reviewed.
Michael B. Fallon
Juan G. Abraldes
Dr. Garcia-Tsao is Professor of Medicine, Chief of Digestive Diseases and Program Director of the Hepatitis C Resource Center at Veteran’s Administration-Connecticut Healthcare System, as well as Director of Clinical and Translational Core at Yale Liver Center. She is a past president of AASLD. She received her M.D. and training at Universidad Nacional Autónoma de Mexico. Her primary research focus is on clinical research which focuses on cirrhosis and its complications, and she also is involved in the study of bacterial infections in cirrhosis, a complication that is often overlooked.
Nicolas M. Intagliata
Clinical Practice SIG: Best Practices in Hepatology 2018Contains 8 Component(s) Recorded On: 11/12/2018
AASLD's Clinical Practice SIG presented at The Liver Meeting® 2018.
This program aims to help attendees understand how to best approach the patient referred for evaluation of an incidentally found liver mass, be better informed on how to conduct office-based noninvasive assessment of liver fibrosis in the patient with elevated liver tests, increase their understanding of the management of alcoholic liver disease in 2018 and have the knowledge to provide care in the post-liver transplant patient in the community setting.
K. Rajender Reddy
Craig J. McClain
Diversity Workshop: Ethnic and Racial Disparities in Liver DiseasesContains 7 Component(s) Recorded On: 11/12/2018
AASLD's Diversity Workshop presented at The Liver Meeting® 2018.
This session will describe the biological and social determinants of health that contribute to ethnic and racial disparities in health and health care; identify the racial and ethnic disparities that have been documented in patients with primary HCC and liver transplantation; and list strategies to prevent viral hepatitis, reduce deaths and decrease health disparities due to HBV and HCV in the U.S.
Kimberly A. Forde
Andrew J. Muir
Dr. Andrew Muir is a gastroenterologist whose research activities are focused on developing innovative treatments for a variety of liver diseases. Through his work at the Durham Veterans Administration Medical Center, Dr. Muir has participated in the development programs of many of the direct acting antiviral agents that have revolutionized hepatitis C care. He assumed the leadership of the Gastroenterology and Hepatology Research program at DCRI in 2010 and has expanded the research portfolio to include other liver disorders and gastroenterology outcomes. His particular interests include viral hepatitis, primary sclerosing cholangitis, and liver transplantation. He also has a longstanding interest in healthcare disparities.
2018 Global Forum: Global Challenges in HCC Risk and SurveillanceContains 8 Component(s) Recorded On: 11/12/2018
AASLD's Global Forum presented at The Liver Meeting® 2018.
HCC is the fifth most common cancer and the third cause of cancer-related deaths worldwide. The underlying liver disease that ultimately leads to HCC varies throughout the world. Identifying the population at risk for HCC is critical in order to implement preventive strategies to reduce the burden of the disease. Moreover, identifying the population at risk will facilitate the use of surveillance programs. This forum will review, in all pertinent regions of the world, the main populations at risk for HCC and discuss strategies for reducing the burden of the disease through prevention and surveillance.
Hashem B. El-Serag
Diana A. Payawal
Flair Jose Carrilho